Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKumar, Ravinder
dc.contributor.authorArora, Sandeep
dc.contributor.authorSyal, Pratima
dc.contributor.authorSippy, Mayank
dc.identifier.issnPrint 2321-2217
dc.identifier.issnOnline 2321-2225
dc.description.abstractRheumatoid arthritis (RA) is a systemic inflammatory connective tissue disease with polyarthritis as a prominent feature; however, extra-articular symptoms and signs are always present. Advanced glycation end products with ability of cross-linking of proteins characteristic fluorescence and reaction with AGE-specific receptor RAGE (receptor for AGEs). AGEs action as well as AGE formation is directly related to both to inflammation and oxidative stress. RAGE is a 35-kDa polypeptide whose gene is located at the junction of the class II and III HLA regions on chromosome. AGE ligation of RAGE has been shown to activate p21ras and mitogen-activated protein (MAP) kinase, and stimulate nuclear translocation of the transcription factor NF-κB, thereby, resulting in the transcription of target genes thus may induce chronic cellular activation and tissue damage.en_US
dc.publisherChitkara University Publicationsen_US
dc.subjectAdvance glycated end productsen_US
dc.subjectRheumatoid arthritisen_US
dc.titleA Review on Role of Advanced Glycation End products (AGEs) in Rheumatoid Arthritisen_US
Appears in Collections:JPTRM Volume 3 Number 1 (May - 2015)

Files in This Item:
File Description SizeFormat 
31001_JPTRM_Ravinder.pdf454.04 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.